Efficacy And Safety Concerns Are Important Reasons Why The FDA Requires Multiple Reviews Before Approval Of New Drugs
Open Access
- 1 April 2015
- journal article
- Published by Health Affairs Publishing, LLC in Health Affairs
- Vol. 34 (4) , 681-688
Abstract
The regulatory approval of new drugs by the Food and Drug Administration (FDA) is a long and complex process and often requires multiple cycles of review, potentially delaying patients’ access to new and effective therapeutics. We used qualitative methods to characterize the safety and efficacy reasons why applications for novel therapeutics approved by the FDA between 2001 and 2011 required multiple review cycles prior to approval. Among ninety-six applications approved between 2001 and 2011 that required multiple review cycles, safety concerns contributed to seventy-four (77.1 percent) and efficacy concerns to forty-three (44.8 percent). Our study suggests that multiple review cycles appear to play an important role in allowing the FDA to protect public health and in ensuring adequate understanding of clinical benefits and risks prior to approval.Keywords
This publication has 14 references indexed in Scilit:
- Scientific and Regulatory Reasons for Delay and Denial of FDA Approval of Initial Applications for New Drugs, 2000-2012JAMA, 2014
- Clinical Trial Evidence Supporting FDA Approval of Novel Therapeutic Agents, 2005-2012JAMA, 2014
- Regulatory Review of Novel Therapeutics — Comparison of Three Regulatory AgenciesNew England Journal of Medicine, 2012
- Study of Neurontin: Titrate to Effect, Profile of Safety (STEPS) TrialArchives of internal medicine (1960), 2011
- Pharmaceutical Innovation in the 21st Century: New Drug Approvals in the First Decade, 2000–2009Clinical Pharmacology & Therapeutics, 2010
- Guest Authorship and Ghostwriting in Publications Related to RofecoxibJAMA, 2008
- What have we learnt from Vioxx?BMJ, 2007
- Narrative Review: The Promotion of Gabapentin: An Analysis of Internal Industry DocumentsAnnals of Internal Medicine, 2006
- Every document and picture tells a story: using internal corporate document reviews, semiotics, and content analysis to assess tobacco advertisingTobacco Control, 2006
- How cigarette design can affect youth initiation into smoking: Camel cigarettes 1983-93Tobacco Control, 2002